Principales études cliniques des iBTK (notice n° 660039)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01487cam a2200289 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121192116.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ysebaert, Loïc |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Principales études cliniques des iBTK |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 77 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | L‘évaluation de la qualité de vie (QDV) est primordiale dans les essais thérapeutiques en hématologie, mais n’est pas du tout reconnue comme le seul vrai critère principal centré sur le patient. Pour les patients atteints de leucémie lymphoïde chronique, comment abandonner la seule survie sans progression afin de vraiment considérer la survie globale en bonne QDV ? |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Quality of life evaluation is a cornerstone of randomized controlled trials in hematology but is now rarely considered as such, and is a often only a secondary endpoint in most studies. For CLL patients, how can we abandon PFS to move to OS in good QOL? |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | qualité de vie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Essais thérapeutiques |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | survie sans progression |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | maladie résiduelle |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | leucémie lymphoïde chronique (LLC) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | residual disease |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Therapeutic trials |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | quality of life |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | CLL |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | progression-free survival |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 30 | N° Supp 1 | 2024-06-02 | p. 44-46 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2024-Supp1-page-44?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2024-Supp1-page-44?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux